Commercial Print Version What is gonorrhea? Gonorrhea is a sexually transmitted disease STD that can infect both men and women.
Print Results indicated that further evaluation of gepotidacin in the treatment of gonorrhea is warranted. Gepotidacin, a novel triazaacenaphthelene bacterial type II topoisomerase inhibitor, shows promise and potential in treating resistant Neisseria gonorrhoeae through a unique interaction, according to study results published in Antimicrobial Agents and Chemotherapy.
The prevalence of gonorrhea infections has risen steadily in recent years, while effective treatment options have decreased as a result of increasing antimicrobial resistance in Neisseria gonorrhoeae.
As a result, novel antibacterial agents and treatment strategies are needed to address the threat of potentially untreatable gonorrhea.
Gepotidacin is a first-in-class triazaacenaphthelene bacterial type II topoisomerase inhibitor being developed for the treatment of gonorrhea by interacting in a unique way against most target pathogens resistant to established antibacterial agents, including drug-resistant N gonorrhoeae strains.
Therefore, this study ClinicalTrials. NCT evaluated microbiologic correlates of successful treatment of N gonorrhoeae isolates in the aforementioned phase 2 study of gepotidacin for therapy of uncomplicated urogenital gonorrhea.
Data was used from the phase 2, randomized, multicenter, open-label, dose-ranging, single oral dose study of gepotidacin mg or mg in a 1: In this study, a single oral dose of gepotidacin was administered at baseline followed by test-of-cure 3 to 7 days after dosing.
Pretreatment and test-of-cure urogenital swab and rectal and pharyngeal specimens were obtained. The evaluable population consisted of 69 randomly assigned participants 67 male and 2 female with culture-confirmed urogenital gonorrhea at baseline who received gepotidacin and returned for test-of-cure.
Of the 69 participants, 2 also had culture-confirmed pharyngeal gonorrhea and 3 had culture-confirmed rectal gonorrhea. Microbiologic success was defined as culture-confirmed eradication of N gonorrhoeae at test-of-cure; microbiologic failure was defined as culture-confirmed bacterial persistence of N gonorrhoeae at time of test-of-cure or the inability to determine the response of the baseline pathogen at test-of-cure.
Isolates that were failures carried mutations implicated in gepotidacin binding sites.At the National STD Prevention Conference in Washington, the CDC reported nearly million US cases of these sexually transmitted diseases were diagnosed in , according to preliminary data.
Gonorrhea is transmitted through contact with an infected vagina, penis, anus, or mouth. It is spread through semen or vaginal fluids during unprotected sexual contact with a partner who has gonorrhea.
Touching infected sex organs, like the vagina or penis, and then touching your eyes can also cause an eye infection. Nov 27, · The prevalence of gonorrhea infections has risen steadily in recent years, I would like to receive relevant information via email from Infectious Disease Advisor / Haymarket Medical Network.
More in Sexually Transmitted Diseases. It's not necessary to have sexual intercourse to get a sexually-transmitted disease (STD).
The human papillomavirus (HPV) that causes genital warts can be transmitted by close skin-to-skin contact. Some types of HPVs cause cervical or anal cancer, and vaccines are available to protect against the most dangerous types.
Gonorrhea. Chlamydia infection is sometimes confused with gonorrhea, another bacterial infection transmitted through vaginal and anal intercourse, and oral sex.
Not only do they share many of the same symptoms, the two diseases can occur together. Gonorrhea usually begins in the urethra (bladder opening) or the cervix. STDs are infections that are transmitted during vaginal, anal, and oral sex.
They are very common and many people who have them don’t show any symptoms.